Key Insights

Highlights

Success Rate

98% trial completion (above average)

Published Results

64 trials with published results (33%)

Research Maturity

132 completed trials (68% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

1.5%

3 terminated out of 194 trials

Success Rate

97.8%

+11.2% vs benchmark

Late-Stage Pipeline

36%

70 trials in Phase 3/4

Results Transparency

48%

64 of 132 completed with results

Key Signals

64 with results98% success

Data Visualizations

Phase Distribution

167Total
Not Applicable (31)
Early P 1 (1)
P 1 (32)
P 2 (33)
P 3 (54)
P 4 (16)

Trial Status

Completed132
Recruiting19
Unknown14
Active Not Recruiting13
Not Yet Recruiting11
Terminated3

Trial Success Rate

97.8%

Benchmark: 86.5%

Based on 132 completed trials

Clinical Trials (194)

Showing 20 of 20 trials
NCT06207487CompletedPrimary

Clinical and Economic Impact of Herpes Zoster in Cancer Patients

NCT05580458Phase 1RecruitingPrimary

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

NCT06569823Phase 1Active Not Recruiting

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

NCT07585370RecruitingPrimary

Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine

NCT07502560Phase 4RecruitingPrimary

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

NCT07569978Not ApplicableNot Yet RecruitingPrimary

Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain

NCT03604406Phase 2CompletedPrimary

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

NCT06375512Phase 1CompletedPrimary

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT06851832Phase 1Active Not RecruitingPrimary

Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older

NCT07361796Not ApplicableRecruitingPrimary

The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster

NCT07481604Phase 2Not Yet RecruitingPrimary

Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

NCT07307170Not ApplicableRecruitingPrimary

The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster

NCT07293065Phase 3Active Not RecruitingPrimary

A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)

NCT04006808Phase 1RecruitingPrimary

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

NCT07400640Recruiting

Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia

NCT07399288CompletedPrimary

Postherpetic Neuralgia After Herpes Zoster and Incident Dementia Risk

NCT07400003Phase 1RecruitingPrimary

Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

NCT06643247Not ApplicableRecruitingPrimary

Electroacupuncture Regulation of Immune Cells in Herpes Zoster

NCT07378046Not ApplicableRecruitingPrimary

The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster

NCT07378059Not ApplicableRecruitingPrimary

The Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster

Scroll to load more

Research Network

Activity Timeline